Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $106.78M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 0.04M
CLLS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cellectis S.A.NASDAQ: CLLS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows in line with its trailing trend
Q1 FY2026 research & development of $23.09M rose 5.3% year over year, in line with the +5.0% change in trailing-twelve-month research & development. Sequentially, it fell 5.5% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.
Context
- Research & development amounted to 128.2% of revenue in FY2025, down 89.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +5.3% holds above the trailing-twelve-month pace of +5.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 93.52M USD
- Year-over-year change
- +3.3%
- 4-year CAGR
- -5.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 93.52M | +3.3% |
| FY2024 | 2024-12-31 | 90.54M | +3.3% |
| FY2023 | 2023-12-31 | 87.65M | -10.1% |
| FY2022 | 2022-12-31 | 97.5M | -17.3% |
| FY2021 | 2021-12-31 | 117.84M | — |
Research & Development vs competitors
How CLLS compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.0% is the 5th highest of 10, against a peer median of -6.9%.
- Research & development amounts to 139.0% of revenue for CLLS, versus a peer median of 1530.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $152.7M USD | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $124.71M USD | +42.2% | +15.6% | — | |
| LTM Mar 2026 | $94.68M USD | +5.0% | -1.4% | 139.0% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | $58.79M USD | -15.8% | +15.8% | 1530.1% | |
| LTM Mar 2026 | $55.94M USD | +19.0% | +24.4% | — | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
| LTM Mar 2026 | $35.87M USD | +29.3% | +13.9% | — | |
| LTM Mar 2026 | $20.65M USD | -58.3% | -18.4% | — | |
| LTM Mar 2026 | $18.45M USD | -6.9% | -13.3% | 8.6% | |
| LTM Mar 2026 | $18.13M USD | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding CLLS) | — | -6.9% | +14.7% | 1530.1% | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.35M | 19.17M | 755K | 41.51M | 72.95M |
| Cost of Revenue | 1.84M | 8.48M | 7.42M | 9.18M | 9.8M |
| Gross Profit | 28.5M | 10.69M | (6.66M) | 32.32M | 63.15M |
| Gross Margin | 93.9% | 55.7% | -882.6% | 77.9% | 86.6% |
| Research & Development | 117.84M | 97.5M | 87.65M | 90.54M | 93.52M |
| Selling, General & Admin | 22.88M | 8.9M | 8.12M | 8.42M | 8.6M |
| Operating Expenses | 131.98M | 100.35M | 90.64M | 91.88M | 96.23M |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.85M | 20.06M |
| EBITDA | (78.43M) | (76.38M) | (92.64M) | (9.46M) | (39.85M) |
| EBITDA Margin | -258.4% | -398.4% | -12269.8% | -22.8% | -54.6% |
| Operating Income | (103.48M) | (89.67M) | (97.3M) | (59.55M) | (33.08M) |
| Operating Margin | -341.0% | -467.7% | -12887.7% | -143.5% | -45.3% |
| Interest Income | 719K | 1.12M | 3.61M | 11.28M | 9.5M |
| Interest Expense | 4.37M | 3.79M | 5.31M | 7.45M | 8.11M |
| Other Income / Expenses | 6.73M | (8.94M) | (19.16M) | 22.79M | (34.94M) |
| Income Before Tax | (96.75M) | (98.6M) | (116.46M) | (36.76M) | (68.02M) |
| Pre-Tax Margin | -318.8% | -514.3% | -15425.7% | -88.6% | -93.2% |
| Income Tax Expense | (3K) | 87K | 371K | 0 | (423K) |
| Net Income | (114.2M) | (106.14M) | (101.06M) | (36.76M) | (67.59M) |
| Net Margin | -376.3% | -553.6% | -13385.3% | -88.6% | -92.7% |
| EPS (Basic) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| EPS (Diluted) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| Weighted Avg Shares | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
| Weighted Avg Shares (Diluted) | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.